Grace Capital’s BridgeBio Pharma BBIO Stock Holding History

Grace Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$1.41M	Buy	84,250 +1,900	+2%	+$80.4K	0.83%	33
2021 Q3	$3.99M	Buy	82,350 +5,000	+6%	+$268K	2.45%	7
2021 Q2	$4.71M	Buy	77,350 +450	+0.6%	+$25.7K	3.16%	6
2021 Q1	$4.74M	Hold	76,900	–	–	3.01%	6
2020 Q4	$5.47M	Buy	76,900 +3,475	+5%	+$168K	3.45%	4
2020 Q3	$2.75M	Sell	73,425 -1,000	-1%	-$31.5K	2.14%	10
2020 Q2	$2.43M	Buy	74,425 +39,925	+116%	+$1.22M	2.08%	6
2020 Q1	$1M	Hold	34,500	–	–	0.98%	27
2019 Q4	$1.21M	Buy	34,500 +11,000	+47%	+$305K	0.99%	23
2019 Q3	$504K	Buy	+23,500	New	+$650K	0.51%	60

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grace Capital's BBIO Position: Q4 2021 in Review

Grace Capital increased its BridgeBio Pharma (BBIO) stake by 2.3% in Q4 2021, buying an estimated $80.4K and bringing the position to 84,250 shares worth $1.41M. The position accounts for 0.83% of the portfolio, ranked #33.

Grace Capital first reported a position in BBIO in Q3 2019 and has held it in 10 quarters since. The position peaked at $5.47M in Q4 2020. 195 funds tracked by Wall St. Rank hold BBIO as of Q4 2021.

Grace Capital held 84,250 shares of BridgeBio Pharma worth $1.41M as of Q4 2021.
Grace Capital bought 1,900 BridgeBio Pharma shares in Q4 2021, an estimated $80.4K.
BridgeBio Pharma made up 0.83% of Grace Capital's portfolio in Q4 2021, its #33 holding.
Grace Capital first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 10 quarters since.
Grace Capital's BridgeBio Pharma position peaked at $5.47M in Q4 2020.
195 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2021.

Based on Grace Capital's 13F filing for Q4 2021, filed 2 Feb 2022.